Press release
Clostridium Difficile Infections Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive Clostridium Difficile Infections Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Clostridium Difficile Infections Pipeline Outlook Report [https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Clostridium Difficile Infections Pipeline Report
* In June 2025, Vedanta Biosciences Inc . announced a study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).
* In June 2025, Crestone Inc. announced a research is to evaluate the primary objectives of safety and efficacy (rate of clinical cure) of 2 dosages of CRS3123 (200 mg and 400 mg) administered orally (po) twice daily (bid) and vancomycin administered 125 mg PO 4 times daily (qid) in adults > or equal to 18 years of age with a primary episode or first recurrence of CDI. The study will investigate the plasma concentrations and HRQoL outcomes of CRS3123 and additional efficacy endpoints as secondary objectives.
* DelveInsight's Clostridium Difficile Infections pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Clostridium Difficile Infections treatment.
* The leading Clostridium Difficile Infections Companies such as Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, Deinove and others.
* Promising Clostridium Difficile Infections Pipeline Therapies such as VE303, Ibezapolstat, Vancomycin, SER-109, RBX2660, MK-6072, MK-3415A, Fidaxomicin and others.
Discover how the Clostridium Difficile Infections treatment paradigm is evolving. Access DelveInsight's in-depth Clostridium Difficile Infections Pipeline Analysis for a closer look at promising breakthroughs @ Clostridium Difficile Infections Clinical Trials and Studies [https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Clostridium Difficile Infections Emerging Drugs Profile
* VE303: Vedanta Biosciences
VE303 is a potential first-in-class live biotherapeutic product candidate being developed by Vedanta Biosciences to prevent recurrence of Clostridioides difficile infection (CDI). It consists of a rationally-designed, defined bacterial consortium of 8 strains of clonal human commensal bacteria selected for their ability to provide colonization resistance to C. difficile. VE303 is administered orally in capsules and is produced under CGMP conditions from pure, clonal bacterial cell banks, yielding a standardized drug product. In a Phase II study, high-dose VE303 met its primary endpoint of preventing CDI recurrence at eight weeks in patients at high risk of recurrence. VE303 was generally well-tolerated in the study. Vedanta is currently enrolling patients into a pivotal Phase III registrational study called RESTORATiVE303 to evaluate the efficacy and safety of VE303 for the prevention of recurrent CD.
* Ibezapolstat: Acurx Pharmaceuticals
Ibezapolstat (formerly named ACX-362E) is our lead antibiotic candidate. Ibezapolstat is a first-in-class of a new class of Pol IIIC inhibitors which is in clinical development to treat C. difficile infections or CDI. In June 2018, ibezapolstat was designated by the US Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted Fast Track designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI. Currently, the drug is in the Phase II stage of its development for the treatment of Clostridium Difficile Infections.
The Clostridium Difficile Infections Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Clostridium Difficile Infections with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Clostridium Difficile Infections Treatment.
* Clostridium Difficile Infections Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Clostridium Difficile Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Clostridium Difficile Infections market
Explore groundbreaking therapies and clinical trials in the Clostridium Difficile Infections Pipeline. Access DelveInsight's detailed report now! @ New Clostridium Difficile Infections Drugs [https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Clostridium Difficile Infections Companies
Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, Deinove and others.
Clostridium Difficile Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Clostridium Difficile Infections Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Clostridium Difficile Infections Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Clostridium Difficile Infections Pipeline Report
* Coverage- Global
* Clostridium Difficile Infections Companies- Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, Deinove and others.
* Clostridium Difficile Infections Pipeline Therapies such as VE303, Ibezapolstat, Vancomycin, SER-109, RBX2660, MK-6072, MK-3415A, Fidaxomicin and others.
* Clostridium Difficile Infections Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Clostridium Difficile Infections Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Clostridium Difficile Infections drug development? Find out in DelveInsight's exclusive Clostridium Difficile Infections Pipeline Report-access it now! @ Clostridium Difficile Infections Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Clostridium Difficile Infections: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Clostridium Difficile Infections- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* VE303: Vedanta Biosciences
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Ibezapolstat: Acurx Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Clostridium Difficile Infections Key Companies
* Clostridium Difficile Infections Key Products
* Clostridium Difficile Infections- Unmet Needs
* Clostridium Difficile Infections- Market Drivers and Barriers
* Clostridium Difficile Infections- Future Perspectives and Conclusion
* Clostridium Difficile Infections Analyst Views
* Clostridium Difficile Infections Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=clostridium-difficile-infections-pipeline-appears-robust-with-20-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Clostridium Difficile Infections Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4082133 • Views: …
More Releases from ABNewswire
Top Fintech Software Development Companies In France
France has become a booming center for financial technology innovation in the last several years. The country has attracted both local and worldwide technology experts who offer top-notch fintech software development services. This is because it has a strong digital infrastructure, more money is being put into fintech firms, and the government is doing things to help. If you want to develop safe, scalable, and compliant fintech solutions, you need…
The Operator Vault Announces How To Setup OpenClaw a Workshop For Non Techies
The Operator Vault, founded by Kevin Jeppesen, announced a new recorded OpenClaw workshop priced at $19 and expanded access to its Operator Vault community for creators and operators building automation systems.
NEW YORK, N.Y. - Feb. 20, 2026 - The Operator Vault, a training platform and community founded by Kevin Jeppesen, today announced the release of a new recorded workshop focused on OpenClaw, a tool used to build practical automation workflows…
Interior Painting Contractor in Philadelphia, PA, Observes Spring Surge as Homeo …
Philadelphia, PA - As temperatures warm and daylight extends, Beauty Walls and Floor is experiencing the annual spring surge that owner Sviat Oleksyuk has come to anticipate each year. The seasonal shift brings a wave of homeowners eager to refresh their living spaces, transforming interiors that may have been neglected during the darker winter months.
"Summer is the best, as well as spring time, when people get inspired with new ideas…
Modern Mountain Home Architects in Asheville, NC Complete Two-Volume Residence o …
Asheville, NC - Vellum Architecture & Design has completed the Windcliff Residence, a striking two-volume private residence positioned at 3,200 feet above sea level on a dramatic ridgeline site in Poplar Ridge. Designed for a professional couple from Florida seeking a modern mountain retreat, the project exemplifies thoughtful integration with the Blue Ridge landscape while navigating stringent height restrictions and complex topography.
The residence's distinctive composition features two volumes connected by…
More Releases for Clostridium
Veterinary Clostridium Vaccine Market
The veterinary clostridium vaccine market plays a crucial role in the prevention of clostridial diseases in livestock and companion animals. Clostridial infections, caused by bacteria from the Clostridium genus, can lead to severe health issues and significant economic losses in the agriculture sector. Vaccination is one of the most effective methods to control these infections, which include conditions like enterotoxemia, tetanus, and gas gangrene. The growing awareness of animal health,…
Clostridium Diagnostics Market Analysis, Size, Share & Trends | 2031
In recent years, the global Clostridium Diagnostics Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Clostridium Diagnostics Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five…
Clostridium Diagnostics Market to Witness Astonishing Growth by 2030
Clostridium Diagnostics market is projected to grow at a CAGR of 7.5% from 2024 to 2030. The growth in this market can be attributed to the increasing incidence of Clostridium-related diseases, rising demand for accurate and rapid diagnosis, and growing awareness about Clostridial infections. Important changes in the business allow key players to attain larger profits. This Clostridium Diagnostics Market study report is the best way to make changes with…
Clostridium Diagnostics Market - Empowering Precision, Defeating Infection: Adva …
Newark, New Castle, USA - new report, titled Clostridium Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Clostridium Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Clostridium Diagnostics market. The report offers an overview of the market, which…
Clostridium Vaccine Market Size, Price, Share | Forecast to 2027
Latest Updated Report 2023, The Global Clostridium Vaccine Market to Growing A CAGR of % during forecast period of 2023-2027. The Market is segmented by Global Clostridium Vaccine Market Breakdown by Application (Veterinary Clinic, Veterinary Hospital) by Type (General Type) and by Geography (North America, South America, Europe, Asia Pacific, MEA).
The Clostridium Vaccine Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It…
Global Clostridium Difficile Immunoassays Market - Opportunities & Forecasts, 20 …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global clostridium difficile immunoassays market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was able…
